| Name | PF-04753299 |
| Description | PF-04753299 is a potent and selective inhibitor of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC), demonstrating bactericidal effects against gonococcal isolates and exhibiting inhibitory activity against E. coli, P. aeruginosa, and K. pneumoniae, with minimum inhibitory concentration (MIC) 90 values of 2 μg/ml, 4 μg/ml, and 16 μg/ml, respectively. This compound is utilized in researching gram-negative bacterial infections [1]. |
| In vivo | Rats were subjected to intraperitoneal challenge with Pseudomonas aeruginosa strain UC12120, a penicillin-resistant, quinolone-susceptible clinical isolate (1a Minimum Inhibitory Concentration MIC = 0.25 μg/mL), at 0.5 hr and 4 hr post-treatment with PF-04753299 (Subcutaneous Dose; Vehicle: 40% β-cyclodextrin dissolved in water). At 24 h post-infection, animals were necropsied and the bacterial load on the spleen was subsequently determined. The dose of compound required to reduce the bacterial load by 50% (ED50) was determined to be 35 mg/kg compared to untreated animals [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 70 mg/mL (201.48 mM), Sonication is recommended.
|
| Keywords | PF-04753299 | PF04753299 | PF 04753299 | LpxC |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate | BES |
| Related Compound Libraries | Bioactive Compound Library | Anti-Gram-Negative Bacterial Library | Inhibitor Library | Anti-Bacterial Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library |
United States
